RecruitingNCT05833932
Suhexiang Pill for Acute Ischemic Stroke: A Registry Study
Suhexiang Pill for Acute Ischemic Stroke: A Prospective Registry Study of Real-world Data
Sponsor
Dongzhimen Hospital, Beijing
Enrollment
1,000 participants
Start Date
Jun 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Acute ischemic stroke within 7 days of symptom onset.
- Age ≥ 18
- Patient who has received Suhexiang Pill treatment
- Patient or legally authorized representative has signed informed consent.
Exclusion Criteria3
- Be allergic to Suhexiang Pill
- Known to be pregnant or breastfeeding.
- With conditions that render outcomes or follow-up unlikely to be assessed.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSuhexiang Pill
Suhexiang Pill is an approved traditional Chinese patent medicine.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05833932
Related Trials
Cerebrospinal Fluid Mitochondrial Biomarkers in Ischemic Stroke and Alzheimer Disease
NCT076009961 location
Goal Attainment Scaling in Upper Limb Spasticity Treatment
NCT049756461 location
Proprioceptive Error Correction for Post-Stroke Upper Limb Rehabilitation
NCT071569551 location
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
NCT055183051 location
Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial
NCT0711155928 locations